Fort Worth, Texas—Over the past two years, eight novel targeted agents have been added to the treatment arsenal for acute myeloid leukemia (AML), making treatment algorithms a bit more complex than the “7+3” chemotherapy induction regimen that has been around for more than 40 years. At the 2019 annual meeting of the Hematology/Oncology Pharmacy Association, Kayleigh R. Marx, PharmD, and Bernard L. Marini, PharmD, shared insights on what clinical pharmacists
AUGUST 15, 2019